STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved

🇩🇪 STAT News Health (DE) —
STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved

AI Summary

German biotech company Immatics is awaiting Phase 3 trial results for its lead melanoma treatment after more than 25 years of work. The results are a pivotal step toward potential regulatory approval.

After a quarter century of work, the German biotech Immatics is facing a pivotal moment as it awaits Phase 3 results for its lead candidate in melanoma.

Markets Health Immatics biotechnology melanoma clinical trial drug approval cancer treatment

Read original source →